Moleculin Biotech CS (MBRX)

$2.79 +0.05 (1.82%)
Market Cap 14.57M
Revenue (ttm) 0.00
Net Income (ttm) -33.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 362,200
Avg Vol 163,718
Day's Range N/A - N/A
Shares Out 5.34M
Stochastic %K 94%
Beta 1.74
Analysts Strong Sell
Price Target $21.00

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 300 5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
fantastex
fantastex May. 29 at 11:01 PM
$MBRX can this go back over 60 dollars?
0 · Reply
NwTre
NwTre May. 29 at 2:22 PM
$MBRX
0 · Reply
focafoca99
focafoca99 May. 29 at 1:35 PM
$MBRX now has new ASCO data backing the differentiated cardiac safety profile of Annamycin. https://www.rapidticker.com/news/mbrx-sec-filing-9a6f7a
0 · Reply
YoloAlfred
YoloAlfred May. 29 at 1:16 PM
$MBRX adding some more
0 · Reply
YoloAlfred
YoloAlfred May. 29 at 12:57 PM
$MBRX added more
0 · Reply
DARKP00L
DARKP00L May. 29 at 12:52 PM
$MBRX 08:27 on May. 29 2026 Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Were Presented At The American Society Of Clinical Oncology Annual Meeting #tradeideas
0 · Reply
DARKP00L
DARKP00L May. 29 at 12:51 PM
$MBRX 08:26 on May. 29 2026 Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting #tradeideas
0 · Reply
YoloAlfred
YoloAlfred May. 29 at 12:32 PM
$MBRX added
0 · Reply
focafoca99
focafoca99 May. 29 at 12:30 PM
$MBRX shared ASCO 2026 data showing no detectable cardiotoxicity with Annamycin even at high exposure levels. https://www.rapidticker.com/news/mbrx-moleculin-presents-asco-2026-data-37f7b3
0 · Reply
MrTicker
MrTicker May. 29 at 12:26 PM
$MBRX Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting BENZINGA 7:26 AM ET 5/29/2026
0 · Reply
Latest News on MBRX
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

May 29, 2026, 8:21 AM EDT - 12 hours ago

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

May 21, 2026, 5:02 PM EDT - 8 days ago

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

May 15, 2026, 8:30 AM EDT - 14 days ago

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Moleculin Biotech Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 15 days ago

Moleculin Biotech Quarterly report: Q1 2026

Moleculin Biotech Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 15 days ago

Moleculin Biotech Earnings release: Q1 2026

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

2026-05-13T14:09:53.000Z - 16 days ago

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

May 13, 2026, 8:00 AM EDT - 16 days ago

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin announces publication on cardiac safety profiloe of annamycin

2026-05-12T19:17:30.000Z - 17 days ago

Moleculin announces publication on cardiac safety profiloe of annamycin

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

May 12, 2026, 9:30 AM EDT - 17 days ago

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

2026-05-08T15:28:54.000Z - 21 days ago

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

May 8, 2026, 8:45 AM EDT - 21 days ago

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Apr 23, 2026, 8:25 AM EDT - 5 weeks ago

Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Apr 21, 2026, 8:36 AM EDT - 5 weeks ago

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

Apr 7, 2026, 8:36 AM EDT - 7 weeks ago

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

Moleculin Biotech management to meet with Maxim

2026-04-02T15:10:34.000Z - 2 months ago

Moleculin Biotech management to meet with Maxim

Moleculin Biotech files to sell 6.37M shares of common stock for holders

2026-03-27T20:07:31.000Z - 2 months ago

Moleculin Biotech files to sell 6.37M shares of common stock for holders

Moleculin Biotech Registration statement: Registration filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Moleculin Biotech Registration statement: Registration filing

Moleculin Biotech Transcript: The 38th Annual Roth Conference

Mar 24, 2026, 3:00 PM EDT - 2 months ago

Moleculin Biotech Transcript: The 38th Annual Roth Conference

Moleculin Biotech announces enrollment milestone in MIRACLE trial

2026-03-23T13:23:25.000Z - 2 months ago

Moleculin Biotech announces enrollment milestone in MIRACLE trial

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

Mar 23, 2026, 8:31 AM EDT - 2 months ago

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

2026-03-19T12:41:28.000Z - 2 months ago

Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

Moleculin Biotech sees cash runway into 3Q26

2026-03-19T12:41:00.000Z - 2 months ago

Moleculin Biotech sees cash runway into 3Q26

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Mar 19, 2026, 8:36 AM EDT - 2 months ago

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Moleculin Biotech Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Moleculin Biotech Earnings release: Q4 2025

Moleculin Biotech Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Moleculin Biotech Annual report: Q4 2025

Moleculin Biotech Slides: Corporate presentation

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Moleculin Biotech Slides: Corporate presentation

Moleculin to Present at 38th Annual ROTH Conference

Mar 17, 2026, 9:05 AM EDT - 2 months ago

Moleculin to Present at 38th Annual ROTH Conference

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Mar 11, 2026, 9:00 AM EDT - 2 months ago

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Moleculin Biotech Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Proxy statement: Proxy Filing

Feb 26, 2026, 7:00 AM EST - 3 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds

2026-02-19T13:44:53.000Z - 3 months ago

Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Feb 19, 2026, 8:39 AM EST - 3 months ago

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Moleculin approach first unblinding of data from Phase 2B/3 study of Annamycin

2026-02-18T13:25:45.000Z - 3 months ago

Moleculin approach first unblinding of data from Phase 2B/3 study of Annamycin

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Feb 18, 2026, 8:20 AM EST - 3 months ago

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Moleculin Biotech Slides: Corporate presentation

Feb 18, 2026, 6:00 AM EST - 3 months ago

Moleculin Biotech Slides: Corporate presentation

Moleculin Biotech announces notice of allowance for JPO covering Annamycin

2026-02-17T14:00:40.000Z - 3 months ago

Moleculin Biotech announces notice of allowance for JPO covering Annamycin

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Feb 17, 2026, 8:35 AM EST - 3 months ago

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Moleculin Biotech announces launch of CEO Corner platform

2026-02-13T13:35:29.000Z - 3 months ago

Moleculin Biotech announces launch of CEO Corner platform

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Feb 13, 2026, 8:32 AM EST - 3 months ago

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Moleculin Biotech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:20 PM EST - 3 months ago

Moleculin Biotech Transcript: Corporate Connect Webinar Series

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 4 months ago

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Moleculin Biotech reports assessment confirms no cardiotoxicity of Annamycin

2026-01-13T14:01:57.000Z - 4 months ago

Moleculin Biotech reports assessment confirms no cardiotoxicity of Annamycin

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Jan 13, 2026, 8:55 AM EST - 4 months ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Moleculin Biotech says first MIRACLE trial unblinding expected in 1Q16

2026-01-12T13:46:34.000Z - 4 months ago

Moleculin Biotech says first MIRACLE trial unblinding expected in 1Q16

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Jan 12, 2026, 8:36 AM EST - 4 months ago

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Moleculin Biotech Proxy statement: Proxy Filing

Jan 2, 2026, 7:00 AM EST - 5 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech files to sell 2.61M shares of common stock for holders

2025-12-23T21:50:21.000Z - 5 months ago

Moleculin Biotech files to sell 2.61M shares of common stock for holders

Moleculin Biotech Registration statement: Registration Filing

Dec 23, 2025, 7:00 AM EST - 5 months ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Proxy statement: Proxy Filing

Dec 22, 2025, 7:00 AM EST - 5 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 5 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech announces results from Phase 1 trial of WP1066

2025-12-17T13:36:21.000Z - 5 months ago

Moleculin Biotech announces results from Phase 1 trial of WP1066

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Dec 17, 2025, 8:31 AM EST - 5 months ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Moleculin Biotech target adjusted to $31 from $300 at Roth Capital

2025-12-15T17:20:30.000Z - 5 months ago

Moleculin Biotech target adjusted to $31 from $300 at Roth Capital

Moleculin Biotech target adjusted to $22 from $4 at H.C. Wainwright

2025-12-11T11:25:22.000Z - 6 months ago

Moleculin Biotech target adjusted to $22 from $4 at H.C. Wainwright

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Dec 10, 2025, 8:30 AM EST - 6 months ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Moleculin Biotech provides update on enrollment for MIRACLE study

2025-12-09T13:15:50.000Z - 6 months ago

Moleculin Biotech provides update on enrollment for MIRACLE study

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 9, 2025, 8:07 AM EST - 6 months ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Moleculin Biotech announces new Annamycin collaboration in brain tumors

2025-12-08T13:30:31.000Z - 6 months ago

Moleculin Biotech announces new Annamycin collaboration in brain tumors

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Dec 8, 2025, 8:21 AM EST - 6 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:15 AM EST - 6 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Moleculin Announces Reverse Stock Split

Nov 26, 2025, 9:00 AM EST - 6 months ago

Moleculin Announces Reverse Stock Split

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 13, 2025, 8:36 AM EST - 7 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Moleculin Biotech Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Moleculin Biotech Quarterly report: Q3 2025

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Nov 12, 2025, 8:37 AM EST - 7 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 30, 2025, 8:40 AM EDT - 7 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 29, 2025, 8:35 AM EDT - 7 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Oct 23, 2025, 8:00 AM EDT - 7 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 25, 2025, 8:35 AM EDT - 8 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Moleculin Biotech Registration statement: Registration Filing

Sep 19, 2025, 8:00 AM EDT - 9 months ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 9 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 9, 2025, 8:45 AM EDT - 9 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 8, 2025, 8:30 AM EDT - 9 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Biotech Proxy statement: Proxy Filing

Sep 5, 2025, 8:00 AM EDT - 9 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 9 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 10 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:05 AM EDT - 10 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin Biotech Earnings release: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Moleculin Biotech Earnings release: Q2 2025

Moleculin Biotech Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Moleculin Biotech Quarterly report: Q2 2025

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Aug 6, 2025, 8:40 AM EDT - 10 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 10 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 11 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 11 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 11 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Moleculin Biotech Proxy statement: Proxy Filing

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Proxy statement: Proxy Filing

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Proxy statement: Proxy Filing

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 1 year ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:45 AM EDT - 1 year ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 18, 2025, 7:30 AM EDT - 1 year ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Biotech Registration statement: Registration Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Registration statement: Registration Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Registration statement: Registration Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Transcript: Study Update

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Transcript: Study Update

Moleculin Biotech Press release: Study Update

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Press release: Study Update

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 1 year ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech Registration statement: Registration Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Earnings Call Transcript: Q1 2025

Moleculin Biotech Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Earnings release: Q1 2025

Moleculin Biotech Quarterly report: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

Moleculin Biotech Quarterly report: Q1 2025

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 1 year ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025, 8:40 AM EDT - 1 year ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

fantastex
fantastex May. 29 at 11:01 PM
$MBRX can this go back over 60 dollars?
0 · Reply
NwTre
NwTre May. 29 at 2:22 PM
$MBRX
0 · Reply
focafoca99
focafoca99 May. 29 at 1:35 PM
$MBRX now has new ASCO data backing the differentiated cardiac safety profile of Annamycin. https://www.rapidticker.com/news/mbrx-sec-filing-9a6f7a
0 · Reply
YoloAlfred
YoloAlfred May. 29 at 1:16 PM
$MBRX adding some more
0 · Reply
YoloAlfred
YoloAlfred May. 29 at 12:57 PM
$MBRX added more
0 · Reply
DARKP00L
DARKP00L May. 29 at 12:52 PM
$MBRX 08:27 on May. 29 2026 Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Were Presented At The American Society Of Clinical Oncology Annual Meeting #tradeideas
0 · Reply
DARKP00L
DARKP00L May. 29 at 12:51 PM
$MBRX 08:26 on May. 29 2026 Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting #tradeideas
0 · Reply
YoloAlfred
YoloAlfred May. 29 at 12:32 PM
$MBRX added
0 · Reply
focafoca99
focafoca99 May. 29 at 12:30 PM
$MBRX shared ASCO 2026 data showing no detectable cardiotoxicity with Annamycin even at high exposure levels. https://www.rapidticker.com/news/mbrx-moleculin-presents-asco-2026-data-37f7b3
0 · Reply
MrTicker
MrTicker May. 29 at 12:26 PM
$MBRX Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting BENZINGA 7:26 AM ET 5/29/2026
0 · Reply
MrTicker
MrTicker May. 29 at 12:22 PM
$MBRX Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits GLOBENEWSWIRE 7:21 AM ET 5/29/2026
0 · Reply
Stock_Catcher
Stock_Catcher May. 29 at 12:21 PM
$MBRX Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
0 · Reply
NwTre
NwTre May. 29 at 8:31 AM
$MBRX 👀
0 · Reply
IVALTE
IVALTE May. 28 at 8:20 PM
$MBRX cuando va a subir esta basura?
0 · Reply
IVALTE
IVALTE May. 28 at 5:34 PM
$MBRX la mona
0 · Reply
Big_Zack22
Big_Zack22 May. 28 at 4:57 PM
$MBRX ❤️
0 · Reply
IVALTE
IVALTE May. 27 at 8:17 PM
$MBRX humo
0 · Reply
Raffaello1214
Raffaello1214 May. 27 at 4:37 PM
$MBRX 🤑next target
0 · Reply
Big_Zack22
Big_Zack22 May. 27 at 2:54 PM
$MBRX 🙌 one of my big invesment
0 · Reply
longsprosper
longsprosper May. 27 at 1:21 AM
$MBRX dead silence with ASCo this weekend. Better plays out there I guess.
0 · Reply
biotrade123
biotrade123 May. 26 at 9:52 PM
$MBRX dead board? this is due for a pop?
0 · Reply
longsprosper
longsprosper May. 23 at 3:42 PM
$MBRX The company presents at ASCO next Saturday, maybe we will get a little bump on price this coming week?
0 · Reply